Transcenta Holding Limited (“Transcenta”) (HKEX: 06628) announces that it has presented updated efficacy data from the expansion cohort of the TranStar102 of Osemitamab (TST001) plus CAPOX chemotherapy study as the first-line treatment of advanced G/GEJ Cancer at the ESMO Congress 2023 in Madrid, Spain.
| |
| [23-October-2023] |
| Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median progression-free survival (PFS) of more than 12 months for all patients treated in the expansion cohort PRINCETON, N.J. and SUZHOU, China, Oct. 23, 2023 /PRNewswire/ -- Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical-stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented updated efficacy data from the expansion cohort of the TranStar102 of Osemitamab (TST001) plus CAPOX chemotherapy study as the first-line treatment of advanced G/GEJ Cancer at the ESMO Congress 2023 in Madrid, Spain. The updated data continued to show encouraging efficacy from previously disclosed data in patients with CLDN18.2 expression ≥10%, ≥1+ per the LDT assay used to select patients. Two additional posters were presented: one on preclinical data supporting the triple combination of Osemitamab (TST001), nivolumab and chemotherapy over Osemitamab (TST001) and chemotherapy including in PD-L1 negative tumors; and one detailing the clinical pharmacology explorations supporting the recommended Phase III dose. “These latest datasets further solidify the evidence affirming the efficacy that Osemitamab (TST001) plus CAPOX chemotherapy can provide as a first-line treatment for advanced gastric and gastroesophageal cancer including in tumors with lower levels of CLDN18.2 expression, and provide the rationale to explore the triple combination of Osemitamab (TST001), nivolumab and chemotherapy regardless of the PD-L1 CPS levels.” said Dr. Caroline Germa, Transcenta’s Executive Vice President, Global Medicine Development and Chief Medical Officer. “We are highly encouraged by the compelling efficacy outcomes from this study in addition to the recent FDA approval to initiate a global Phase III clinical trial, which signifies that Osemitamab (TST001) is poised to redefine the prevailing standard of care for patients with CLDN18.2 positive, HER2 negative gastric and gastroesophageal cancers.” Study Design Cohort C from Transtar102 study (NCT04495296) was designed to explore the safety and efficacy of Osemitamab (TST001) plus CAPOX as first-line treatment in advanced G/GEJ cancer. In this study, 49 patients were enrolled and treated with 6mg/kg Q3W Osemitamab (TST001) and CAPOX in the efficacy expansion cohort. Among the 49 patients enrolled, 41 patients had CLDN18.2 positive tumors, and the other 8 patients did not have the biomarker tested. CLDN18.2 expression were tested using the IHC 14G11 LDT assay in a central laboratory. CLDN18.2 positive tumor was defined as ≥ 10% tumor cells staining at least 1+ by the LDT assay, which represents approximately 55% of all the G/GEJ cancer patients. Encouraging and Durable mDOR and mPFS At the cut-off date reported here, the median follow-up for the 49 patients was 11.3 months with the longest treatment duration over 1.5 years. Among the 49 patients, 42 patients had measurable lesions at baseline and at least one post-baseline tumor assessment, and 28 of them achieved partial response, with 23 as confirmed response (54.8%, 23/42). The median duration of response (DoR) of these 23 responders was 12.7 months. 20 patients of the 49 patients had progression of disease or death, with an estimated median progression-free survival (PFS) of 14 months. The median overall survival (OS) was not reached because of the limited number of events, the 12-month survival rate for the overall population of cohort-C (64 patients, all doses) was 88.9% (95% CI: 74.2, 95.4). This further supports the Phase III trial strategy of combining Osemitamab (TST001) with nivolumab and chemotherapy in 1L CLDN18.2 positive G/GEJ cancer which Transcenta received FDA clearance recently. Favorable and Manageable Safety Profile The safety profile of these 49 patients was mainly characterized by manageable on-target-off-tumor effects, including nausea, hypoalbuminemia, and vomiting, most of them were grade 1 or 2 and occurred during the first 2 cycles. In addition, preclinical data presented at the congress (#1560P) showed significant upregulation of PD-L1 in gastric cancer cells and increased TIL infiltration into tumor upon treatment with Osemitamab (TST001). The combination of anti-CLDN18.2 Osemitamab (TST001) with PD1 inhibitor nivolumab and chemotherapy resulted in significant synergy including in a CLDN18.2 positive/PD-L1 negative PDX model of gastric cancer. 5/8, 2/8, 0/8, 0/8 of the mice treated with Osemitamab (TST001) plus nivolumab and chemotherapy, Osemitamab (TST001) and chemotherapy, nivolumab and chemotherapy or chemotherapy only achieved tumor clearance in the mouse model respectively. In an ER analysis of data from 58 patients with 1L G/GEJ adenocarcinoma treated with Osemitamab (TST001) and CAPOX, trends of longer PFS/DoR and higher durable ORR were associated with higher Osemitamab (TST001) exposure and was aligned with exposure range achieved by 6 mg/kg Q3W. Safety ER analyses didn’t demonstrate clinically significant increase in risk when dose increased from 3 to 6 mg/kg Q3W. Preliminary efficacy, safety and PK/PD data demonstrates favorable benefit risk profile and support future exploration of Osemitamab (TST001) at the dose of 6mg/kg Q3W or 4mg/kg Q2W. About Osemitamab (TST001) Osemitamab (TST001) is a high affinity humanized anti-CLDN18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (“ADCC”). It has shown potent anti-tumor activities in tumor xenograft models. Osemitamab (TST001) is the second most advanced CLDN18.2 targeting antibody being developed globally. Osemitamab (TST001) was generated using Transcenta’s Immune Tolerance Breaking Technology (IMTB) platform. Osemitamab (TST001) kills CLDN18.2 expressing tumor cells by mechanisms of ADCC. Leveraging advanced bioprocessing technology, the fucose content of Osemitamab (TST001) was significantly reduced during the production, which further enhanced NK cells mediated ADCC activity of Osemitamab (TST001). Clinical trials for Osemitamab (TST001) are ongoing in the U.S. and China (NCT05190575, NCT04396821, NCT04495296, NCT05608785 / CTR20201281). Osemitamab (TST001) was granted Orphan Drug Designation in the U.S. by FDA for the treatment of patients with gastric or gastroesophageal junction (G/GEJ) and pancreatic cancer. About Transcenta Holding Limited Transcenta (HKEX: 06628) is a clinical stage biopharmaceutical company with fully integrated capabilities in antibody-based biotherapeutics discovery, research, development and manufacturing. Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Princeton, US and in Beijing, Shanghai and Guangzhou of China, and External Partnering Center in Boston and Los Angeles, US. Transcenta has also initiated the construction of the Group Headquarters and the second high-end biopharmaceutical facility with ICB as its core technology in Suzhou Industrial Park. Transcenta is developing 13 therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. For more information, please visit www.transcenta.com and https://www.linkedin.com/company/transcenta. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Transcenta, are intended to identify certain of such forward-looking statements. Transcenta does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Transcenta with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Transcenta’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Transcenta’s competitive environment and political, economic, legal and social conditions. Transcenta, the Directors and the employees of Transcenta assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. Transcenta and Osemitamab are trademarks of Transcenta Holding Limited. All other brands and product names may be trademarks and/or registered trademarks of their respective owners.
SOURCE Transcenta Holding Limited | ||
Company Codes: HongKong:6628 |
View original content:
